Design Therapeutics Reports Q3 2026 Loss of $20.3 Million and GAAP EPS of -$0. ...
Clinical-Stage GeneTAC Developer Reports $208.6 Million Cash Position as Lead Friedreich Ataxia Program Advances Toward 2027 Data Readouts Related Stocks: DSGN ,
Clinical-Stage GeneTAC Developer Reports $208.6 Million Cash Position as Lead Friedreich Ataxia Program Advances Toward 2027 Data Readouts Related Stocks: DSGN ,